Proteinaceous adjuvants
US7105161B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 8, 1995 |
| Grant date | Sep 12, 2006 |
| Priority date | — |
| Expiry date | Jun 8, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxified pertussis holotoxin, particularly one retaining its immunogenicity, to a host. The modulated immune response enables immunogenic compositions, including multivalent pediatric vaccines such as DTP, to be provided which produce a modulated immune response in the absence of extrinsic adjuvants such as alum. The adjuvanting effect achieved by the genetically-detoxified pertussis holotoxin enables at least the same level of adjuvanting effect to be achieved as previously attained by alum, without the undesirable side effects thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.